4.1 based on 9 reviewsView this provider's reviews
Patient satisfaction ratings and reviews are based on personal opinions. Before you choose any doctor you should take into account their background, training, specialized experience AND their patient satisfaction to ensure they are the right fit for you.
Accepting new patients
As the Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, Dr. Carvajal is focused on the development of novel therapies for patients with melanoma and other cancers, with the overall objective of controlling and curing these diseases. To achieve this goal, he has used our increasing knowledge of the underlying biology of cancer to rapidly integrate this knowledge, novel therapeutic agents, and efficient trial design in order to improve the outcomes of cancer patients everywhere. Working closely with the laboratory scientists, the group is using the techniques of molecular biology to identify specific proteins, genes, or other molecules that influence the growth of each person's cancer, with the goal of selecting the most promising therapies for individual patients. Dr. Carvajal's melanoma research has included the study and treatment of uncommon clinical and molecular subsets of melanoma such as melanomas arising from the eye (uveal melanomas), from the mucosal surfaces of the body (mucosal melanomas), and from the palms of the hands, soles of the feet, or under the fingernails (acral melanomas). Although these tumors arise from pigment cells of the body just as do the more common melanomas that arise from the skin (cutaneous melanomas), they are clinically and biologically distinct from cutaneous disease. Once metastatic (that is, spread from where it originally began to other sites in the body), these diseases have proven to be difficult to treat. In an advance that helped to launch a new era of personalized medicine in melanoma therapy, Dr. Carvajal has led a clinical trial of imatinib (Gleevec) in patients with melanoma characterized by the presence of a mutation in a gene called KIT. While this mutation is rare in cutaneous melanoma, it is found in about 20% of mucosal and acral melanomas. Based in part on the positive results of this trial, where long-lasting tumor responses were observed in patients with these diseases, the use of imatinib in melanomas harboring KIT mutations was added to the National Comprehensive Cancer Network guidelines for the treatment of melanoma. Uveal melanoma is characterized by mutations in genes called GNAQ and GNA11 that lead to activation of a growth pathway called the MAPK pathway. Before 2013, there were no effective treatments for metastatic disease; however, another trial that Dr. Carvajal has developed and conducted identified selumetinib, a medicine that blocks the MAPK pathway, as the first effective treatment for patients with advanced uveal melanoma. Dr. Carvajal's research has been supported by the National Cancer Institute, the Food and Drug Administration, the Conquer Cancer Foundation, the Melanoma Research Alliance, the Melanoma Research Foundation, the Empire Clinical Research Investigator Program, and the generous philanthropic support of our patients and their families. He has authored or co- authored more than 50 peer-reviewed manuscripts, books, and book chapters. In addition to Dr. Carvajal's work at Columbia University Medical Center, he serves as the co-chair of the International Rare Cancer Initiative Uveal Melanoma working group, a joint initiative between the National Cancer Institute, the European Organization for Research and Treatment of Cancer, and the Cancer Research UK to enhance international collaboration in the conduct of clinical trials for uveal melanoma.
We're trying something new with Top Care Areas.Was it helpful for you?YesNo
This content was provided by Dr. Carvajal "We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person. "
Accredited by: American Board of Internal Medicine*
Accredited by: American Board of Internal Medicine*
Adrenal Gland Cancer
Anal and Rectal Cancer
Antiphospholipid Syndrome (APS)
Basal Cell Carcinoma
Bile Duct Cancer
Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
Coagulation Disorders (incl. Hemophilia)
Deep Vein Thrombosis (DVT)
Fallopian Tube Cancer
Gallbladder and Biliary Tract Cancer
Head and Neck Cancer
Immune Thrombocytopenic Purpura (ITP)
Lung Neoplasms, Not Specified as Malignant
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Mediastinal Tumors, Malignant
Mediastinal Tumors, Not Specified as Malignant
Merkel Cell Carcinoma
Polycythemia Rubra Vera
Primary Hypercoagulable State (incl. Factor V Leiden Disease)
Salivary Gland Cancer
Small Intestine Cancer
Soft Tissue Sarcoma
Squamous Cell Carcinoma
Stomach and Small Intestine Cancer
Throat Cancer (Hypopharyngeal)
Throat Cancer (Nasopharyngeal)
Venous Embolism and Thrombosis
Vertebral Column Tumors
Bone Marrow Biopsy
Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
0 Malpractice Claims
No malpractice history found for New York.
No sanctions history found for the years that Healthgrades collects data.
0 Board Actions
No board actions found for the years that Healthgrades collects data.
New York University School Of Medicine
Medical School | Graduated 2000
University Of Michigan Hospitals
Residency Hospital | Completed 2003
Memorial Sloan Kettering
Fellowship Hospital | Completed 2007
Awards & Recognition
Awards & Honors
Healthgrades Honor Roll
Media & Publications
Dr. Carvajal has no media or publications listed.
Memberships & Professional Affiliations
Dr. Carvajal does not have any memberships or affiliations listed. If you are Dr. Carvajal and would like to add memberships or affiliations, please update your profile.